X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
EP395 is an oral small molecule drug candidate, which is currently being evaluated for the treatment of patients suffering from chronic obstructive pulmonary disease.
Lead Product(s): EP395
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: EP395
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2024
Details:
EP395 is an orally available macrolide or ‘Barriolide™,’ with reduced antimicrobial resistance potential, which aims to address the unmet medical need for a treatment for COPD.
Lead Product(s): EP395
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: EP395
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2022
Details:
EP395 is an orally available macrolide or ‘Barriolide™‘ with reduced antimicrobial activity which aims to address the unmet medical need for a treatment for COPD (Chronic Obstructive Pulmonary Disease).
Lead Product(s): EP395
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: EP395
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2022
Details:
EP395, is the first of EpiEndo’s orally available, non-antibiotic macrolides or ‘Barriolides™’, to enter clinical development and will be targeting chronic obstructive pulmonary disease (COPD).
Lead Product(s): EP395
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: EP395
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2022
Details:
The financing secures funds to advance clinical development of EpiEndo’s lead compound EP395, which entered phase I clinical trials in April, through Phase IIa, targeting COPD as a primary indication.
Lead Product(s): EP395
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: EP395
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Flerie Invest
Deal Size: $23.6 million Upfront Cash: Undisclosed
Deal Type: Series A Financing August 18, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
